Jiangsu Hengrui Medicine Co., Ltd.

This phase 3 trial tested a new drug called HRG2010 in 165 people with Parkinson's disease who experience motor fluctuations—times when their symptoms return before the next dose. The study compared HRG2010 to a standard sustained-release levodopa to see if it could reduce daily …

This study tests a new medicine called SHR-3167 against a standard insulin (insulin glargine) for people with type 2 diabetes. About 275 adults who are not on insulin yet, but take metformin (alone or with another diabetes drug), will receive either SHR-3167 or insulin glargine. …

This study tested a new drug called HRS-9190 against a standard muscle relaxant (rocuronium) in 103 adults having surgery. The goal was to see how quickly muscles recover after the last dose. Researchers also checked for side effects. The drug is meant to keep muscles relaxed dur…

This study tested a new drug called HR19042 in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug can reduce protein in the urine, a sign of kidney damage, and find the best dose. Participants took either the drug or a placebo for a set period, and…

This early-phase study tested a new drug called HRS7415 in 38 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see if the drug could help control the disease. Researchers monitored side effects and measured drug levels in…

This study tested a combination of two drugs, SHR-1210 (given through a vein) and Apatinib (a daily pill), in 210 adults with advanced non-small cell lung cancer that had stopped responding to standard chemotherapy. The goal was to see if the combo could shrink tumors and to chec…

This study tested a combination of two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), in 190 adults with advanced liver cancer that did not respond to or could not tolerate prior treatment. The goal was to see if the combination could shrink tumors and cont…

This early-phase study tested a new drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific protein called HER2. The main goals were to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants h…

This study tested a new combination treatment for people with advanced liver cancer or bile duct cancer. The treatment combines an immunotherapy drug (SHR-1210) with either a targeted therapy (apatinib) or chemotherapy. The goal was to see if the combination is safe and can shrin…

This study tested a new medicine called HRS-9190 in 70 adults having planned surgery. The medicine is a muscle relaxant given during anesthesia to help doctors place a breathing tube more easily. Researchers compared it to a standard drug to see if it works as well and is safe. T…

This Phase 3 trial tested whether a new injectable drug, HR17031, works better than standard insulin glargine for controlling blood sugar in Chinese adults with type 2 diabetes. The study included 401 people whose diabetes was not well controlled with oral medications. Researcher…

This Phase 3 trial tested a new drug called HR17031 against the standard insulin glargine in 393 adults with type 2 diabetes whose blood sugar was not well controlled despite using basal insulin and metformin. The study measured changes in HbA1c (average blood sugar), weight, and…

This Phase 3 trial tested a targeted cancer pill called pyrotinib against standard chemotherapy (docetaxel) in 151 people with advanced non-squamous non-small cell lung cancer that has a specific HER2 mutation. All participants had already tried platinum-based chemo without succe…

This phase 2 trial tested whether adding rivoceranib to camrelizumab after surgery or ablation helps prevent liver cancer from coming back in high-risk patients. 251 participants were randomly assigned to receive either the combination or camrelizumab alone. The main goal was to …

This study tested a new tablet called HR091506 in 765 adults with gout and high uric acid. The goal was to see if it could lower uric acid levels better than an existing drug, febuxostat. Participants took the medicine for 28 weeks, and doctors checked their uric acid levels regu…

This Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…

This early-phase trial tested a drug called SHR-A1811 in 396 people with advanced solid tumors that have HER2 expression or mutations and have stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body, while also lookin…

This phase 3 trial tested whether an oral tablet called SHR7280 works as well as the standard injection (ganirelix) for preventing early ovulation in women undergoing IVF. The study involved 317 infertile women aged 20-39. If effective, the pill could offer a more convenient opti…

This completed Phase 3 trial tested a special PET-CT scan using a radioactive tracer called gallium-68 DOTATOC to find neuroendocrine tumors in the stomach, intestines, and pancreas. 69 adults with confirmed or suspected tumors received the scan. The goal was to see how accuratel…

This study tested a drug called remimazolam to see how well it works and how safe it is for sedating children and teenagers during surgery. About 249 young patients took part. The goal was to see if the drug could successfully start and maintain sedation while keeping side effect…

This Phase 3 trial tested a sedative called remimazolam tosilate in 214 ICU patients who were on breathing machines. The goal was to see if it works as well as or better than the standard sedative propofol. Patients received either remimazolam or propofol, and researchers measure…

This early-stage study tested the safety and effects of a new drug called HRS-9190, designed to relax skeletal muscles. 49 healthy adults received either a single dose or a continuous infusion of the drug, sometimes with other medications. Researchers monitored side effects and h…

This early-phase trial tested a sedative called remimazolam tosilate in 24 ICU patients who needed to be on a breathing machine for at least three days. The goal was to see if the drug could keep patients at the right sedation level safely. Because this is a small, non-randomized…

This study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …

This study looked at how two common drugs (ritonavir and itraconazole) change the way the body processes a new experimental drug called SHR-A1811 in people with advanced HER2-positive breast cancer. Seventeen participants received the drug alone and then with each of the other me…

This study looked at how a single dose of HR17031 moves through the body in people with mild, moderate, severe, or end-stage kidney disease compared to those with normal kidneys. A total of 24 adults with type 2 diabetes took part. The goal was to understand how kidney function a…

This early-stage trial tested the safety and how the body processes a new drug called HR011408 in 62 healthy adults. Participants received two different versions of the drug to compare them. The goal was to check for side effects and measure drug levels in the blood, not to treat…

This early-phase trial tested a single injection of a new drug called SHR-3167 alongside standard insulin glargine in 24 healthy men. The goal was to compare how the drugs affect blood sugar and how the body processes them. The study focused on safety and basic drug behavior, not…

This completed Phase 1 study looked at how an experimental drug called HRS-8427 affects the liver's ability to process other medications. Fourteen healthy adults took HRS-8427 along with two common drugs (bupropion and midazolam) to see if it changed their levels in the blood. Th…

This early-stage study tested a new injection called HRS-9190 in 53 healthy adults aged 18 to 45. The main goal was to check safety and how the body processes different doses. No treatment for any condition was given; this was purely to gather safety and dosing information for fu…

This study looked at the safety of a sedative called remimazolam tosilate when used for general anesthesia and during a breathing tube procedure (bronchoscopy). Over 1,200 patients were observed in real-world medical settings in China. The main goal was to track any side effects …

This completed study observed over 2,000 patients in China who received remimazolam, a short-acting sedative, during painless gastroscopy or colonoscopy. The goal was to collect real-world safety information, including side effects and serious adverse events. No new treatment was…

This study checked whether a new form of the painkiller bupivacaine (liposomal) is absorbed in the body the same way as the approved version. It involved 36 healthy adults aged 18-45. The goal was to measure drug levels in the blood, not to treat pain directly.

This completed Phase 1 study looked at how the drug SHR8554 injection behaves in 20 people with kidney problems compared to healthy volunteers. The goal was to measure drug levels and safety, not to treat pain. Results will help guide future dosing for patients with kidney issues…

This completed phase 1 study tested how SHR7280, a drug being developed for endometriosis and uterine fibroids, affects the way the body processes six other common drugs. Twenty healthy men took SHR7280 along with midazolam, warfarin, omeprazole, digoxin, and rosuvastatin to see …

This completed Phase 1 study tested how the antibiotic rifampicin changes the way the body processes HRS-5041, an experimental drug for prostate cancer. Sixteen healthy men took HRS-5041 with and without rifampicin to measure drug levels and safety. The goal was to understand pot…